WeightSnap Tools / Weight loss calculator
What did the trials actually show? Enter your starting weight and pick a medication and dose. This applies the average weight loss from that drug's pivotal clinical trial to your number, milestone by milestone.
| Milestone | Avg. loss | Weight |
|---|
Each figure is the least-squares mean percentage weight change reported in the medication's pivotal trial, the same headline numbers cited in the drug labels and coverage. The milestone rows scale that endpoint back along the typical titration curve, so earlier points are estimates of the path, not separately published values.
Semaglutide 2.4 mg averaged about 15% at 68 weeks in STEP 1. Tirzepatide averaged about 15%, 19.5%, and 20.9% at 5, 10, and 15 mg over 72 weeks in SURMOUNT-1. Retatrutide averaged about 17%, 23%, and 24% at 4, 8, and 12 mg over 48 weeks in its phase 2 trial. Retatrutide is investigational and not yet FDA approved.
In STEP 1, semaglutide 2.4 mg averaged about 15% over 68 weeks versus about 2.4% on placebo. That is an average across nearly 2,000 people; individual results ranged widely.
In SURMOUNT-1, about 15% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg over 72 weeks. Averages, with wide individual spread.
In the phase 2 trial, about 17% at 4 mg, 23% at 8 mg, and 24% at 12 mg over 48 weeks. Investigational and not yet FDA approved.
No. It applies a trial average to your starting weight as a reference point, not a forecast. Your outcome depends on many personal factors and is not medical advice.
GLP-1 weight loss builds gradually during dose titration. Showing the average at earlier points is a more honest picture of the slow, steady curve than a single end figure.
WeightSnap is a tracking tool, not medical advice. This calculator applies published clinical-trial average percentages to the weight you enter; it is a reference point, not a prediction, and results vary widely between individuals. Always work with your healthcare provider.
WeightSnap